Medication Savings
We're sorry, but we're unable to process your login. Please try again.
We're sorry, you are not authorized to access this site. Please contact your local Merck KGaA, Darmstadt, Germany representative.
This page requires you to register for an account with Merck KGaA, Darmstadt, Germany.

Sign-in
{* #signInForm *}
{* signInEmailAddress *}
{* currentPassword *}
{* captcha *}
{* /signInForm *}

Financial support matters when navigating treatment

Infertility treatment can be expensive, but we’re here to help. There are a number of programs available that can help you afford treatment cycles.

The cost of infertility

Today, cycle interruptions and other uncertainty has caused even more financial stress. Our savings programs are designed to help make medications more affordable, so cost doesn’t get in the way of your quest to start a family.  

medication

IF YOUR TREATMENT HAS BEEN AFFECTED BY COVID-19

Replacement Drug Program

 

EMD Serono offers replacement medication to eligible patients who have had a cycle cancelled due to COVID-19. You may be eligible for drug replacement if cycle cancellation took place:

  • after your stimulation cycle began
  • before your egg retrieval procedure

 

If you feel these criteria may apply to your situation, ask your doctor to contact the EMD Serono Fertility Network Pharmacy who filled your prescription to begin the application for replacement medication at no charge.* 

 

*Subject to eligibility; restrictions apply.

IF YOU’RE AN ELIGIBLE, SELF-PAY PATIENT

Compassionate Care

 

The first program of its kind, Compassionate Care was designed to make fertility treatments more affordable if your medications aren’t covered by insurance. The program enrolled over 9,000 patients in 2018, saving them more than $12.8 million.*

 

Compassionate Care provides discounts off the self-pay price of EMD Serono fertility medications, including:

  • For income-based eligible patients, savings of 25%, 50%, or 75%
  • For active, retired, and veteran military, a minimum of 25% off and based on income, up to 75% off

 

Apply online now

 

*Data based on average year-to-date savings.

Subject to eligibility; restrictions apply. View program eligibility requirements and terms and conditions for more information.

View eligibility requirements
  • Eligible income-based patients may save 25%, 50%, or 75% off the self-pay price of EMD Serono fertility medicine or receive a 10% discount per unit, via a mail-in rebate, off their out-of-pocket costs for EMD Serono fertility medications
  • Eligible active/inactive military personnel and veterans receive a minimum of 25% off and might be eligible for additional savings up to 50% or 75% off the self-pay price of EMD Serono fertility medications
  • A minimum purchase is not required for eligibility
 

Compassionate Care covers the following treatments:

  • Gonal-f® RFF* Redi-ject® (follitropin alfa injection) 300 IU, Gonal-f®  RFF* Redi-ject® (follitropin alfa injection) 450 IU, Gonal-f® RFF* Redi-ject® (follitropin alfa injection) 900 IU, Gonal-f®  Multi-Dose (follitropin alfa for injection) 450 IU, Gonal-f® Multi-Dose (follitropin alfa for injection) 1050 IU, Gonal-f® RFF* (follitropin alfa for injection) 75 IU, single vial pack, Gonal®  RFF* (follitropin alfa for injection) 75 IU, 10 vial pack, Cetrotide® (cetrorelix acetate injection), and Ovidrel®  PreFilled Syringe (choriogonadotropin alfa injection).


Compassionate Care Eligibility & Terms

  • Eligibility is based on qualifying annual household gross income and first-time participation in the Compassionate Care program. Program is available only at participating pharmacies. Patients must present a valid prescription for an eligible drug
  • Eligible patients can use the Compassionate Care Program for multiple cycles each year
  • Patients must reapply each year
  • Benefit for patients with demonstrated financial need and a valid prescription for Gonal-f® (follitropin alfa for injection), Ovidrel® PreFilled syringe (choriogonadotropin alfa injection), or Cetrotide® (cetrorelix acetate injection)
  • Benefit is available at participating pharmacies only
  • Qualifying income-based patients can save 75%, 50%, or 25% off the available self-pay price at the participating pharmacy
  • Qualifying eligible active/inactive military personnel and veterans receive a minimum of 25% off the available self-pay price at the participating pharmacy
  • Patients must present a valid prescription for an eligible drug at a participating pharmacy
  • EMD Serono reserves the right to rescind, revoke, terminate, or amend the Compassionate Care program at any time without notice
  • Offer not valid if any prescriptions or expenses associated with fertility treatment will be paid for by private or public insurance or reimbursed under a federal or state healthcare program, including Medicare, Medicaid, TRICARE, the Department of Veterans Affairs, the Department of Defense, or any other similar state healthcare program, including any other similar state medical pharmaceutical assistance program. If you become insured by any private or
  • government insurance, you must notify  the EMD Serono Compassionate Care program by calling 1-855-541-5926
  • Patients may not combine this card with  any rebate, coupon, free trial, or similar offer
  • Program is not transferable and expires one year after program enrollment, unless earlier terminated by EMD Serono
  • Compassionate Care is not an insurance program
  • For US patients only who are 18 years or older

 

*RFF = revised formulation female.
Eligibility based on qualifying annual household gross income and first-time participation in the program.

GO Direct Rebate

 

Patients saved more than $1.8 million in 2018 with the GO Direct Rebate program.*

 

If you’re an eligible self-pay patient, you may be able to receive a 10% discount via rebate off your out-of-pocket costs for the following EMD Serono products:

  • Gonal-f® (follitropin alfa for injection) 10% off per 75 IU
  • Cetrotide® (cetrorelix acetate for injection) 10% off per 0.25 mg
  • Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection) 10% off per 0.25 mg
 

Apply online now

 

*Data based on average year-to-date savings.
†Subject to eligibility; restrictions apply. View program eligibility requirements and terms and conditions for more information.

View eligibility requirements

GO Direct Mail-in Rebate Covers the Following Treatments, Gonal-f® RFF* Redi-ject® (follitropin alfa injection) 300 IU, Gonal-f® RFF* Redi-ject® (follitropin alfa injection) 450 IU, Gonal-f® RFF* Redi-ject® (follitropin alfa injection) 900 IU, Gonal-f® Multi-Dose (follitropin alfa for injection), 450 IU, Gonal-f® Multi-Dose (follitropin alfa for injection) 1050 IU, Gonal-f® RFF* (fallitropin alfa for injection) 75 IU, single-vial pack, Gonal-f® RFF* (follitropin alfa for injection) 75 IU, 10-vial pack, Cetrotide® (cetrorelix acetate), Ovidrel® PreFilled Syringe (choriogonadotropin alfa)

 

GO Direct Mail-in Rebate Eligibility and Terms

  • For US patients only who are 18 years or older
  • Offer not valid if any prescriptions or expenses associated with fertility treatment will be paid for by private or public insurance or reimbursed under a federal or state healthcare program, including Medicare, Medicaid, TRICARE, the Department of Veterans Affairs, the Department of Defense, or any similar state healthcare program, including any state medical pharmaceutical assistance program. If you become insured by any private insurance you must notify the EMD Serono Compassionate Care program by calling 1-855-541-5926
  • Program is available only for US patients and for prescriptions filled in the United States
  • Valid submissions must be mailed in and include the original pharmacy receipt and completed GO Direct to Savings rebate form
  • EMD Serono reserves the right to rescind, revoke, terminate, or amend the program, in whole or in part, at any time without notice
  • This program cannot be combined with any other EMD Serono savings program including special EMD Serono donor pricing
  • If you have any questions, please call 1-866-441-9463
  • This is not an insurance program

 

*RFF = revised formulation female.

IF YOU’RE AN ELIGIBLE, UNINSURED VETERAN

Compassionate Corps

 

Compassionate Corps provides free medication to eligible, uninsured veterans injured in the line of duty or their spouses.* Veterans who do not qualify for the Compassionate Corps program may still receive 25%–75% off their medications through the Compassionate Care program.

 

To become a participating member, your clinic can contact EMD Serono directly at Fertility.Marketing@EMDSerono.com.

 

Download patient application

 

*Subject to eligibility; restrictions apply.

View eligibility requirements
  • To be eligible for the Compassionate Corps program, you must be a retired member of the military or the spouse of one, and a veteran or the spouse of a veteran who meets each of the following criteria:
    • Is infertile due to a service-related injury
    • Is not privately or publicly insured for infertility medications
    • Is medically retired
    • Has been diagnosed by a physician as infertile and requiring in-vitro fertilization (IVF)/assisted reproductive technology (ART)
    • Is not eligible for coverage under the Fertility Veterans Act
  • The Compassionate Corps program is available for up to 2 cycles per year
  • Patients must reapply each year
  • Patients may not combine this offer with any rebate, coupon, free trial card, or similar offer
  • EMD Serono reserves the right to rescind, revoke, terminate, or amend the Compassionate Corps program at any time without notice
  • Offer not valid for prescriptions that may be covered under private or public insurance or reimbursed under a federal or state healthcare program, including Medicare, Medicaid, TRICARE, the Department of Veterans Affairs, the Department of Defense, or any other similar state healthcare program, including any state medical pharmaceutical assistance program. If you become insured by any private or government insurance, you must notify the EMD Serono Compassionate Corps program by calling 1-855-541-5926
  • Compassionate Corps is not an insurance program
  • This program is secondary to coverage provided under the Fertility Veterans Act (Pub. Law 114-223) and does not apply to veterans eligible for coverage under the Act 

FOR QUALIFIED PATIENTS LIVING WITH CANCER

LIVESTRONG Foundation

 

EMD Serono is the sole donor of fertility medications to oncology patients in need* through the LIVESTRONG Fertility Discount program. Since 2004, over 11,500 patients with cancer have received medication donations totaling more than $54.6 million.

 

Apply online now

 

*Terms and conditions for qualification are determined solely by LIVESTRONG. Details can be found at LIVESTRONG.org.

 


More financial support

Explore other treatment financing and savings options

See programs
Medication savings

Taking our medications

View easy-to-follow steps for self-injection

Watch videos
Taking our medications

QUESTIONS?

Call 1-866-LETS-TRY to talk to a Fertility LifeLines® representative today.

or send an email

IMPORTANT RISK INFORMATION & INDICATIONS AND USAGE

Summary of Contraindications

Gonal-f® RFF* Redi-ject®, Gonal-f® Multi-Dose and Gonal-f® RFF* 75 IU are contraindicated in patients with prior hypersensitivity to rhFSH or excipients, high levels of FSH indicating primary gonadal failure, pregnancy, uncontrolled thyroid, adrenal or pituitary disorders, sex hormone dependent tumors of the reproductive tract/accessory organs, tumors of pituitary gland or hypothalamus, abnormal uterine bleeding of undetermined origin and ovarian cyst or enlargement of undetermined origin.

Please scroll for full IMPORTANT RISK INFORMATION or see full Prescribing Information for Gonal-f® RFF* Redi-ject®, Gonal-f® Multi-Dose and Gonal-f® RFF* 75 IU.

* RFF: Revised Formulation Female

Important Risk Information for Gonal-f® RFF* Redi-ject® (follitropin alfa injection)

Do not use Gonal‐f® RFF* Redi‐ject® if you:

  • are allergic to recombinant human FSH or any of the ingredients listed on the product carton or package insert
  • have levels of FSH indicating primary gonadal failure
  • are pregnant or think you may be pregnant due to the potential hazard to a fetus
  • have uncontrolled thyroid, adrenal or pituitary problems
  • have a tumor in your female organs, including your ovaries, breast, or uterus
  • have a tumor in your brain, such as a tumor in your pituitary or hypothalamus
  • have abnormal bleeding from your uterus or vagina
  • have ovarian cysts or large ovaries with unknown cause, not due to polycystic ovary syndrome (PCOS)

Before using Gonal‐f® RFF* Redi‐ject®, tell your healthcare provider about your medical history including any prescription or over- the-counter medicines, vitamins and herbal supplements used, whether you have or have had asthma, abdominal surgery, ovarian cysts, polycystic ovarian disease, blood clots (thrombosis) or family history of blood clots, or are breastfeeding or plan to breastfeed.

Gonal‐f® RFF* Redi‐ject® may cause serious side effects, including:

  • Severe or fatal allergic reactions. Stop using Gonal‐f® RFF* Redi‐ject® and go to the hospital right away if you have symptoms of an allergic reaction which can include shortness of breath, swelling of your face, itchy, red bumps or rash on your skin (hives).
  • Stomach bloating or pain caused by enlargement of your ovaries, or fluid build-up in your stomach, chest and heart caused by ovarian hyperstimulation syndrome (OHSS). OHSS can require hospitalization and in rare cases has caused death. Call your healthcare provider right away if you have symptoms of OHSS, including trouble breathing, severe lower stomach (pelvic) area pain, decreased urine output, nausea, vomiting, weight gain, and diarrhea. 
  • Gonal-f® RFF* can also cause or worsen lung problems (including severe shortness of breath and asthma), blood and blood vessel problems (including clots and stroke) which in rare cases have caused death. 
  • Twisting of your ovary, which requires medical attention.
  • Chances of having a baby with birth defects may increase in a baby born after an ART cycle and can be impacted by maternal age, paternal sperm problems, and genetic background associated with the egg and sperm.
  • Use of Gonal‐f® RFF* Redi‐ject® can result in pregnancy with more than 1 baby and the birth of multiple babies. 
  • Ectopic pregnancy (pregnancy outside your womb).
  • An increased risk of miscarriage. 
  • If you have used fertility medicines like Gonal‐f® RFF* Redi‐ject® before to get pregnant, you may have an increased chance of having tumors in your ovary(ies) (including cancer).
  • Ultrasound and lab tests should be used to monitor treatment.

The most common side effects of Gonal‐f® RFF* Redi‐ject® include:

  • In Ovulation Induction headache, abdominal pain, and ovarian hyperstimulation
  • In ART - abdominal pain, nausea, abdominal enlargement, headache and injection site bruising 

These are not all the possible side effects of Gonal‐f® RFF* Redi‐ject®. For more information, read the product labeling, and ask your healthcare provider or pharmacist.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1‐800‐FDA‐1088.

Use Gonal‐f® RFF* Redi‐ject® as directed and do not change your dose unless directed. Do not share your Gonal‐f® RFF* Redi‐ject® and needles with another person; you may give another person an infection or get an infection from them.

Carefully review the Gonal‐f® RFF* Redi‐ject® Instructions for Use that comes with the Pen for information about the correct use of Gonal‐f® RFF* Redi‐ject® and follow all training and instruction provided by your healthcare provider.

Indications and Usage

Gonal‐f® RFF* Redi‐ject® (follitropin alfa injection) is a prescription medicine containing follicle‐stimulating hormone (FSH) used in infertile women to:

  • help ovulation and pregnancy in women who are infertile due to a cause other than primary ovarian failure
  • cause your ovaries to make multiple (more than 1) eggs as part of an Assisted Reproductive Technology (ART) program 

 For complete information, please see full Prescribing information here.

*RFF, Revised Formulation Female

Important Risk Information for Gonal-f® Multi-Dose (follitropin alfa for injection)

Do not use Gonal‐f® Multi-Dose if you:

  • Are allergic to recombinant human FSH or any of the ingredients listed on the product carton or insert
  • Have uncontrolled thyroid or adrenal problems
  • Have a tumor in your female organs, including your ovaries, breast, or uterus or permanent damage to the male sex organs (testes)
  • Have a tumor in your brain, such as a tumor in your pituitary 
  • Have abnormal bleeding from your uterus or vagina
  • Have ovarian cysts or large ovaries, not due to polycystic ovary syndrome (PCOS)
  • Are pregnant or think you may be pregnant

Before using Gonal‐f® Multi-Dose, tell your healthcare provider about your medical history including any prescription or over- the-counter medicines, vitamins and herbal supplements used, whether you have or have had asthma, abdominal surgery, ovarian cysts, polycystic ovarian disease, blood clots (thrombosis) or family history of blood clots, or are breastfeeding or plan to breastfeed.

Gonal‐f® Multi-Dose may cause serious side effects, including:

  • Ovarian hyperstimulation syndrome (OHSS) is a serious side effect. OHSS can be mild, moderate or severe, and in rare cases, has caused death. Mild symptoms can progress to more serious symptoms and immediate evaluation by your doctor is necessary. Early signs of OHSS include trouble breathing, severe lower stomach (pelvic) area pain, nausea, vomiting, weight gain. Call your health care provider right away. Symptoms include stomach pain, stomach bloating, nausea, vomiting and diarrhea, enlargement of ovaries, difficulty breathing and a drop in urine output
  • Gonal-f® Multi-Dose can also cause or worsen lung problems (including acute respiratory distress syndrome and asthma), blood and blood vessel problems (including clots and stroke) which in rare cases have caused death.
  • Use of Gonal‐f® Multi-Dose can result in pregnancy with more than one baby and the birth of multiple babies.
  • Stop using Gonal‐f® and go to the hospital right away if you have symptoms of an allergic reaction which can include shortness of breath, swelling of your face, itchy, red bumps or rash on your skin (hives).

Other serious side effects include:

  • Gonal‐f® Multi-Dose can also cause or worsen lung problems (including asthma), blood and blood vessel problems (including clots and stroke), or twisting of your ovary, which require medical attention
  • Miscarriage, or ectopic pregnancy (pregnancy outside your womb)
  • Chances of having a baby with birth defects may increase in a baby born after an ART cycle and can be impacted by maternal age, paternal sperm problems, and genetic background associated with the egg and sperm.
  • It is not known if this drug is excreted in human milk. Because of the potential for serious adverse reactions in the nursing infant from Gonal-f, a decision should be made whether to stop nursing or stop the drug taking into account the importance of the drug to the mother.

The most common side effects of Gonal‐f® Multi-Dose include 

  • Headache 
  • Stomach pain 
  • Stomach bloating 
  • Bruising at the injection site,
  • Nausea
  • Other side effects reported include sinus infections and ovarian cysts.

In men, common side effects include 

  • Skin pimples 
  • Breast pain and growth
  • Tiredness.

These are not all the possible side effects of Gonal‐f®. For more information, read the product labeling, and ask your healthcare provider or pharmacist.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1‐800‐FDA‐1088.

Use Gonal‐f® Multi-Dose as directed and do not change your dose unless directed. Do not share your Gonal‐f® Multi-Dose and needles with another person; you may give another person an infection or get an infection from them.

Carefully review the Gonal‐f® Multi‐Dose Patient Information Leaflet that comes with the product and follow all training and instruction provided by your healthcare provider. The injection syringes provided with the product should only be used with Gonal‐f® Multi‐Dose and should not be used to administer any other drug or hormone.

Indications and Usage

Gonal‐f® Multi-Dose is a prescription medicine containing follicle‐stimulating hormone (FSH) used in infertile women to:

  • Help ovulation and pregnancy in women who are infertile due to a cause other than primary ovarian failure
  • Cause your ovaries to make multiple (more than 1) eggs as part of an Assisted Reproductive Technology (ART) program

Gonal‐f® Multi-Dose can also be prescribed to increase sperm production in men with a rare medical condition.

 

Important Risk Information for Gonal-f® RFF* 75 IU (follitropin alfa for injection)

Do not use Gonal‐f® RFF* 75 IU if you:

  • are allergic to recombinant human FSH or any of the ingredients listed on the product carton or package insert
  • have levels of FSH indicating primary gonadal failure
  • have uncontrolled thyroid or adrenal problems
  • have a tumor in your female organs, including your ovaries, breast, or uterus
  • have a tumor in your brain, such as a tumor in your pituitary or hypothalamus
  • have abnormal uterine bleeding of undetermined origin
  • have ovarian cysts or large ovaries, not due to polycystic ovary syndrome (PCOS)
  • are pregnant or think you may be pregnant

Before using Gonal-f® RFF* 75 IU, tell your healthcare provider about your medical history including any prescription or over-the-counter medicines, vitamins and herbal supplements used.

Gonal‐f® RFF* 75 IU may cause serious side effects, including: 

  • Severe or fatal allergic reactions. Stop using Gonal‐f® RFF* 75 IU and go to the hospital right away if you have symptoms of an allergic reaction which can include shortness of breath, swelling of your face, itchy, red bumps or rash on your skin (hives).
  • Stomach bloating or pain caused by enlargement of your ovaries, or fluid build-up in your stomach, chest and heart caused by ovarian hyperstimulation syndrome (OHSS). OHSS can require hospitalization and in rare cases has caused death. Call your healthcare provider right away if you have symptoms of OHSS, including trouble breathing, severe lower stomach (pelvic) area pain, decreased urine output, nausea, vomiting, weight gain, and diarrhea. 
  • Gonal‐f® RFF* 75 IU can also cause or worsen lung problems (including asthma), blood and blood vessel problems (including clots and stroke), or twisting of your ovary, which require medical attention.
  • Use of Gonal‐f® RFF* 75 IU can result in pregnancy with more than one baby and the birth of multiple babies. 
  • It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in the nursing infant from Gonal-f® RFF* 75 IU, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

The most common side effects of Gonal‐f® RFF* 75 IU include headache, stomach pain, stomach bloating, bruising at the injection site, and nausea. Other side effects reported include sinus infections and ovarian cysts. 

These are not all the possible side effects of Gonal‐f® RFF* 75 IU. For more information, read the product labeling, and ask your healthcare provider or pharmacist.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1‐800‐FDA‐1088.

Use Gonal‐f® RFF* 75 IU as directed and do not change your dose unless directed. Do not share your Gonal‐f® RFF* 75 IU and needles with another person; you may give another person an infection or get an infection from them.

Indications and Usage

Gonal‐f® RFF* 75 IU (follitropin alfa for injection) is a prescription medicine containing follicle‐stimulating hormone (FSH) used in infertile women to:

  • help ovulation and pregnancy in women who are infertile due to a cause other than primary ovarian failure
  • cause your ovaries to develop multiple (more than one) eggs as part of an Assisted Reproductive Technology (ART) program
*RFF, Revised Formulation Female

Important Risk Information for Cetrotide® (cetrorelix acetate for injection)

Who should not use Cetrotide®?

  • Patients that are allergic to cetrorelix acetate, mannitol, or exogenous peptide hormones (medicines similar to Cetrotide®) should not use Cetrotide®
  • If you have had severe allergic reactions to any drugs in a previous IVF cycle, tell your doctor.
  • Cetrotide® should not be used in patients who are pregnant, think they might be pregnant, or are breastfeeding.
  • Cetrotide® should not be used in patients with kidney disease.

Before starting Cetrotide®, tell your healthcare professional about all your medical conditions. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements

What is the most important information I should know before starting Cetrotide®?

  • Your doctor will confirm you are not pregnant.

What are the possible side effects of Cetrotide®?

Cetrotide® may cause serious side effects including:

  • Allergic reactions including anaphylactic reaction with the first dose. Treatment with Cetrotide® is not advised in women with severe allergic conditions.
  • Your doctor should review with you the risks and benefits of using Cetrotide®.
  • It is not known if Cetrotide® is excreted in human milk. Because the effects of Cetrotide® on nursing mothers or the nursing infant are not known, do not use Cetrotide® if you are breastfeeding.

Common side effects of using Cetrotide® include:

  • Mild and short-lasting reactions may occur at the injection site like reddening, itching, and swelling. Nausea and headache have also been reported.

Call your doctor if you have any other side effect or if you are unsure about the effect of this medicine.

These are not all the possible side effects of Cetrotide®. For more information, read the product labeling, and ask your healthcare provider or pharmacist.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1‐800‐FDA‐1088.

Indication

What are the uses of Cetrotide®?

Cetrotide® blocks the effects of a natural hormone, called gonadotropin-releasing hormone (GnRH). GnRH controls the secretion of another hormone, called luteinizing hormone (LH), which induces ovulation during the menstrual cycle.

Cetrotide® blocks undesirable premature ovulation. Premature ovulation may lead to eggs that are not available for egg retrieval.

 Please see full Prescribing information here.

Important Risk Information for Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection)

Who should not use Ovidrel® PreFilled Syringe?

Ovidrel® Pre-Filled Syringe should not be used in patients:

  • With allergies to hCG or any other ingredients in the medication
  • With primary ovarian failure (the ovaries no longer produce eggs)
  • With uncontrolled thyroid or adrenal disease
  • Cancer of the brain such as pituitary tumor
  • With a history of abnormal bleeding from the uterus or vagina
  • With swollen, enlarged, or painful ovaries
  • With cancer of the sex organs
  • Who are pregnant 

Before starting Ovidrel®, tell your healthcare professional about all your medical conditions. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What is the most important information I should know before taking Ovidrel?

  • Mild to moderate uncomplicated ovarian enlargement which may be accompanied by abdominal distention and/or abdominal pain may occur in patients treated with FSH and hCG. 
  • Ovarian Hyperstimulation Syndrome (OHSS) may progress rapidly from uncomplicated ovarian enlargement and become a serious medical event. Early signs of OHSS include severe pelvic pain, nausea, vomiting, and weight gain. Call your doctor right away if you think you might be having symptoms of OHSS.
  • Treatment with Ovidrel® may result in becoming pregnant with more than one baby.
  • Blood clots may result from treatment with Ovidrel®.
  • It is not known whether this drug is present in human milk. Because many drugs are excreted in human milk, tell your doctor if you are nursing.

What are the most common side effects of Ovidrel® Pre-Filled Syringe?

The most common side effects in women using Ovidrel® Pre-Filled Syringe include abdominal pain, nausea, and vomiting. Needle injections may cause some discomfort.

These are not all the possible side effects of Ovidrel®. For more information, read the product labeling, and ask your healthcare provider or pharmacist.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1‐800‐FDA‐1088.

Indication

What are the uses of Ovidrel® Pre-Filled Syringe (choriogonadotropin alfa for injection)?

Ovidrel® Pre-Filled Syringe (choriogonadotropin alfa injection) is indicated for the final egg maturation to get ready for egg retrieval. Women who receive Ovidrel® have undergone pituitary desensitization and have been appropriately pre-treated with follicle stimulating hormone (FSH) as a part of an Assisted Reproductive Technology (ART) program such as in vitro (IVF) fertilization and embryo transfer.

Ovidrel® Pre-Filled Syringe is also indicated for the induction of ovulation (OI) and pregnancy in infertile patients who do not ovulate, and in whom the cause of infertility is functional and not due to primary ovarian failure

 For complete information, please see full Prescribing information here.

IMPORTANT RISK INFORMATION & INDICATIONS AND USAGE

Summary of Contraindications

Gonal-f® RFF* Redi-ject®, Gonal-f® Multi-Dose and Gonal-f® RFF* 75 IU are contraindicated in patients with prior hypersensitivity to rhFSH or excipients, high levels of FSH indicating primary gonadal failure, pregnancy, uncontrolled thyroid, adrenal or pituitary disorders, sex hormone dependent tumors of the reproductive tract/accessory organs, tumors of pituitary gland or hypothalamus, abnormal uterine bleeding of undetermined origin and ovarian cyst or enlargement of undetermined origin.

Please scroll for full IMPORTANT RISK INFORMATION or see full Prescribing Information for Gonal-f® RFF* Redi-ject®, Gonal-f® Multi-Dose and Gonal-f® RFF* 75 IU.

* RFF: Revised Formulation Female

Important Risk Information for Gonal-f® RFF* Redi-ject® (follitropin alfa injection)

Do not use Gonal‐f® RFF* Redi‐ject® if you:

  • are allergic to recombinant human FSH or any of the ingredients listed on the product carton or package insert
  • have levels of FSH indicating primary gonadal failure
  • are pregnant or think you may be pregnant due to the potential hazard to a fetus
  • have uncontrolled thyroid, adrenal or pituitary problems
  • have a tumor in your female organs, including your ovaries, breast, or uterus
  • have a tumor in your brain, such as a tumor in your pituitary or hypothalamus
  • have abnormal bleeding from your uterus or vagina
  • have ovarian cysts or large ovaries with unknown cause, not due to polycystic ovary syndrome (PCOS)

Before using Gonal‐f® RFF* Redi‐ject®, tell your healthcare provider about your medical history including any prescription or over- the-counter medicines, vitamins and herbal supplements used, whether you have or have had asthma, abdominal surgery, ovarian cysts, polycystic ovarian disease, blood clots (thrombosis) or family history of blood clots, or are breastfeeding or plan to breastfeed.

Gonal‐f® RFF* Redi‐ject® may cause serious side effects, including:

  • Severe or fatal allergic reactions. Stop using Gonal‐f® RFF* Redi‐ject® and go to the hospital right away if you have symptoms of an allergic reaction which can include shortness of breath, swelling of your face, itchy, red bumps or rash on your skin (hives).
  • Stomach bloating or pain caused by enlargement of your ovaries, or fluid build-up in your stomach, chest and heart caused by ovarian hyperstimulation syndrome (OHSS). OHSS can require hospitalization and in rare cases has caused death. Call your healthcare provider right away if you have symptoms of OHSS, including trouble breathing, severe lower stomach (pelvic) area pain, decreased urine output, nausea, vomiting, weight gain, and diarrhea. 
  • Gonal-f® RFF* can also cause or worsen lung problems (including severe shortness of breath and asthma), blood and blood vessel problems (including clots and stroke) which in rare cases have caused death. 
  • Twisting of your ovary, which requires medical attention.
  • Chances of having a baby with birth defects may increase in a baby born after an ART cycle and can be impacted by maternal age, paternal sperm problems, and genetic background associated with the egg and sperm.
  • Use of Gonal‐f® RFF* Redi‐ject® can result in pregnancy with more than 1 baby and the birth of multiple babies. 
  • Ectopic pregnancy (pregnancy outside your womb).
  • An increased risk of miscarriage. 
  • If you have used fertility medicines like Gonal‐f® RFF* Redi‐ject® before to get pregnant, you may have an increased chance of having tumors in your ovary(ies) (including cancer).
  • Ultrasound and lab tests should be used to monitor treatment.

The most common side effects of Gonal‐f® RFF* Redi‐ject® include:

  • In Ovulation Induction headache, abdominal pain, and ovarian hyperstimulation
  • In ART - abdominal pain, nausea, abdominal enlargement, headache and injection site bruising 

These are not all the possible side effects of Gonal‐f® RFF* Redi‐ject®. For more information, read the product labeling, and ask your healthcare provider or pharmacist.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1‐800‐FDA‐1088.

Use Gonal‐f® RFF* Redi‐ject® as directed and do not change your dose unless directed. Do not share your Gonal‐f® RFF* Redi‐ject® and needles with another person; you may give another person an infection or get an infection from them.

Carefully review the Gonal‐f® RFF* Redi‐ject® Instructions for Use that comes with the Pen for information about the correct use of Gonal‐f® RFF* Redi‐ject® and follow all training and instruction provided by your healthcare provider.

Indications and Usage

Gonal‐f® RFF* Redi‐ject® (follitropin alfa injection) is a prescription medicine containing follicle‐stimulating hormone (FSH) used in infertile women to:

  • help ovulation and pregnancy in women who are infertile due to a cause other than primary ovarian failure
  • cause your ovaries to make multiple (more than 1) eggs as part of an Assisted Reproductive Technology (ART) program 

 For complete information, please see full Prescribing information here.

*RFF, Revised Formulation Female

Important Risk Information for Gonal-f® Multi-Dose (follitropin alfa for injection)

Do not use Gonal‐f® Multi-Dose if you:

  • Are allergic to recombinant human FSH or any of the ingredients listed on the product carton or insert
  • Have uncontrolled thyroid or adrenal problems
  • Have a tumor in your female organs, including your ovaries, breast, or uterus or permanent damage to the male sex organs (testes)
  • Have a tumor in your brain, such as a tumor in your pituitary 
  • Have abnormal bleeding from your uterus or vagina
  • Have ovarian cysts or large ovaries, not due to polycystic ovary syndrome (PCOS)
  • Are pregnant or think you may be pregnant

Before using Gonal‐f® Multi-Dose, tell your healthcare provider about your medical history including any prescription or over- the-counter medicines, vitamins and herbal supplements used, whether you have or have had asthma, abdominal surgery, ovarian cysts, polycystic ovarian disease, blood clots (thrombosis) or family history of blood clots, or are breastfeeding or plan to breastfeed.

Gonal‐f® Multi-Dose may cause serious side effects, including:

  • Ovarian hyperstimulation syndrome (OHSS) is a serious side effect. OHSS can be mild, moderate or severe, and in rare cases, has caused death. Mild symptoms can progress to more serious symptoms and immediate evaluation by your doctor is necessary. Early signs of OHSS include trouble breathing, severe lower stomach (pelvic) area pain, nausea, vomiting, weight gain. Call your health care provider right away. Symptoms include stomach pain, stomach bloating, nausea, vomiting and diarrhea, enlargement of ovaries, difficulty breathing and a drop in urine output
  • Gonal-f® Multi-Dose can also cause or worsen lung problems (including acute respiratory distress syndrome and asthma), blood and blood vessel problems (including clots and stroke) which in rare cases have caused death.
  • Use of Gonal‐f® Multi-Dose can result in pregnancy with more than one baby and the birth of multiple babies.
  • Stop using Gonal‐f® and go to the hospital right away if you have symptoms of an allergic reaction which can include shortness of breath, swelling of your face, itchy, red bumps or rash on your skin (hives).

Other serious side effects include:

  • Gonal‐f® Multi-Dose can also cause or worsen lung problems (including asthma), blood and blood vessel problems (including clots and stroke), or twisting of your ovary, which require medical attention
  • Miscarriage, or ectopic pregnancy (pregnancy outside your womb)
  • Chances of having a baby with birth defects may increase in a baby born after an ART cycle and can be impacted by maternal age, paternal sperm problems, and genetic background associated with the egg and sperm.
  • It is not known if this drug is excreted in human milk. Because of the potential for serious adverse reactions in the nursing infant from Gonal-f, a decision should be made whether to stop nursing or stop the drug taking into account the importance of the drug to the mother.

The most common side effects of Gonal‐f® Multi-Dose include 

  • Headache 
  • Stomach pain 
  • Stomach bloating 
  • Bruising at the injection site,
  • Nausea
  • Other side effects reported include sinus infections and ovarian cysts.

In men, common side effects include 

  • Skin pimples 
  • Breast pain and growth
  • Tiredness.

These are not all the possible side effects of Gonal‐f®. For more information, read the product labeling, and ask your healthcare provider or pharmacist.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1‐800‐FDA‐1088.

Use Gonal‐f® Multi-Dose as directed and do not change your dose unless directed. Do not share your Gonal‐f® Multi-Dose and needles with another person; you may give another person an infection or get an infection from them.

Carefully review the Gonal‐f® Multi‐Dose Patient Information Leaflet that comes with the product and follow all training and instruction provided by your healthcare provider. The injection syringes provided with the product should only be used with Gonal‐f® Multi‐Dose and should not be used to administer any other drug or hormone.

Indications and Usage

Gonal‐f® Multi-Dose is a prescription medicine containing follicle‐stimulating hormone (FSH) used in infertile women to:

  • Help ovulation and pregnancy in women who are infertile due to a cause other than primary ovarian failure
  • Cause your ovaries to make multiple (more than 1) eggs as part of an Assisted Reproductive Technology (ART) program

Gonal‐f® Multi-Dose can also be prescribed to increase sperm production in men with a rare medical condition.

 

Important Risk Information for Gonal-f® RFF* 75 IU (follitropin alfa for injection)

Do not use Gonal‐f® RFF* 75 IU if you:

  • are allergic to recombinant human FSH or any of the ingredients listed on the product carton or package insert
  • have levels of FSH indicating primary gonadal failure
  • have uncontrolled thyroid or adrenal problems
  • have a tumor in your female organs, including your ovaries, breast, or uterus
  • have a tumor in your brain, such as a tumor in your pituitary or hypothalamus
  • have abnormal uterine bleeding of undetermined origin
  • have ovarian cysts or large ovaries, not due to polycystic ovary syndrome (PCOS)
  • are pregnant or think you may be pregnant

Before using Gonal-f® RFF* 75 IU, tell your healthcare provider about your medical history including any prescription or over-the-counter medicines, vitamins and herbal supplements used.

Gonal‐f® RFF* 75 IU may cause serious side effects, including: 

  • Severe or fatal allergic reactions. Stop using Gonal‐f® RFF* 75 IU and go to the hospital right away if you have symptoms of an allergic reaction which can include shortness of breath, swelling of your face, itchy, red bumps or rash on your skin (hives).
  • Stomach bloating or pain caused by enlargement of your ovaries, or fluid build-up in your stomach, chest and heart caused by ovarian hyperstimulation syndrome (OHSS). OHSS can require hospitalization and in rare cases has caused death. Call your healthcare provider right away if you have symptoms of OHSS, including trouble breathing, severe lower stomach (pelvic) area pain, decreased urine output, nausea, vomiting, weight gain, and diarrhea. 
  • Gonal‐f® RFF* 75 IU can also cause or worsen lung problems (including asthma), blood and blood vessel problems (including clots and stroke), or twisting of your ovary, which require medical attention.
  • Use of Gonal‐f® RFF* 75 IU can result in pregnancy with more than one baby and the birth of multiple babies. 
  • It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in the nursing infant from Gonal-f® RFF* 75 IU, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

The most common side effects of Gonal‐f® RFF* 75 IU include headache, stomach pain, stomach bloating, bruising at the injection site, and nausea. Other side effects reported include sinus infections and ovarian cysts. 

These are not all the possible side effects of Gonal‐f® RFF* 75 IU. For more information, read the product labeling, and ask your healthcare provider or pharmacist.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1‐800‐FDA‐1088.

Use Gonal‐f® RFF* 75 IU as directed and do not change your dose unless directed. Do not share your Gonal‐f® RFF* 75 IU and needles with another person; you may give another person an infection or get an infection from them.

Indications and Usage

Gonal‐f® RFF* 75 IU (follitropin alfa for injection) is a prescription medicine containing follicle‐stimulating hormone (FSH) used in infertile women to:

  • help ovulation and pregnancy in women who are infertile due to a cause other than primary ovarian failure
  • cause your ovaries to develop multiple (more than one) eggs as part of an Assisted Reproductive Technology (ART) program
*RFF, Revised Formulation Female

Important Risk Information for Cetrotide® (cetrorelix acetate for injection)

Who should not use Cetrotide®?

  • Patients that are allergic to cetrorelix acetate, mannitol, or exogenous peptide hormones (medicines similar to Cetrotide®) should not use Cetrotide®
  • If you have had severe allergic reactions to any drugs in a previous IVF cycle, tell your doctor.
  • Cetrotide® should not be used in patients who are pregnant, think they might be pregnant, or are breastfeeding.
  • Cetrotide® should not be used in patients with kidney disease.

Before starting Cetrotide®, tell your healthcare professional about all your medical conditions. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements

What is the most important information I should know before starting Cetrotide®?

  • Your doctor will confirm you are not pregnant.

What are the possible side effects of Cetrotide®?

Cetrotide® may cause serious side effects including:

  • Allergic reactions including anaphylactic reaction with the first dose. Treatment with Cetrotide® is not advised in women with severe allergic conditions.
  • Your doctor should review with you the risks and benefits of using Cetrotide®.
  • It is not known if Cetrotide® is excreted in human milk. Because the effects of Cetrotide® on nursing mothers or the nursing infant are not known, do not use Cetrotide® if you are breastfeeding.

Common side effects of using Cetrotide® include:

  • Mild and short-lasting reactions may occur at the injection site like reddening, itching, and swelling. Nausea and headache have also been reported.

Call your doctor if you have any other side effect or if you are unsure about the effect of this medicine.

These are not all the possible side effects of Cetrotide®. For more information, read the product labeling, and ask your healthcare provider or pharmacist.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1‐800‐FDA‐1088.

Indication

What are the uses of Cetrotide®?

Cetrotide® blocks the effects of a natural hormone, called gonadotropin-releasing hormone (GnRH). GnRH controls the secretion of another hormone, called luteinizing hormone (LH), which induces ovulation during the menstrual cycle.

Cetrotide® blocks undesirable premature ovulation. Premature ovulation may lead to eggs that are not available for egg retrieval.

 Please see full Prescribing information here.

Important Risk Information for Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection)

Who should not use Ovidrel® PreFilled Syringe?

Ovidrel® Pre-Filled Syringe should not be used in patients:

  • With allergies to hCG or any other ingredients in the medication
  • With primary ovarian failure (the ovaries no longer produce eggs)
  • With uncontrolled thyroid or adrenal disease
  • Cancer of the brain such as pituitary tumor
  • With a history of abnormal bleeding from the uterus or vagina
  • With swollen, enlarged, or painful ovaries
  • With cancer of the sex organs
  • Who are pregnant 

Before starting Ovidrel®, tell your healthcare professional about all your medical conditions. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What is the most important information I should know before taking Ovidrel?

  • Mild to moderate uncomplicated ovarian enlargement which may be accompanied by abdominal distention and/or abdominal pain may occur in patients treated with FSH and hCG. 
  • Ovarian Hyperstimulation Syndrome (OHSS) may progress rapidly from uncomplicated ovarian enlargement and become a serious medical event. Early signs of OHSS include severe pelvic pain, nausea, vomiting, and weight gain. Call your doctor right away if you think you might be having symptoms of OHSS.
  • Treatment with Ovidrel® may result in becoming pregnant with more than one baby.
  • Blood clots may result from treatment with Ovidrel®.
  • It is not known whether this drug is present in human milk. Because many drugs are excreted in human milk, tell your doctor if you are nursing.

What are the most common side effects of Ovidrel® Pre-Filled Syringe?

The most common side effects in women using Ovidrel® Pre-Filled Syringe include abdominal pain, nausea, and vomiting. Needle injections may cause some discomfort.

These are not all the possible side effects of Ovidrel®. For more information, read the product labeling, and ask your healthcare provider or pharmacist.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1‐800‐FDA‐1088.

Indication

What are the uses of Ovidrel® Pre-Filled Syringe (choriogonadotropin alfa for injection)?

Ovidrel® Pre-Filled Syringe (choriogonadotropin alfa injection) is indicated for the final egg maturation to get ready for egg retrieval. Women who receive Ovidrel® have undergone pituitary desensitization and have been appropriately pre-treated with follicle stimulating hormone (FSH) as a part of an Assisted Reproductive Technology (ART) program such as in vitro (IVF) fertilization and embryo transfer.

Ovidrel® Pre-Filled Syringe is also indicated for the induction of ovulation (OI) and pregnancy in infertile patients who do not ovulate, and in whom the cause of infertility is functional and not due to primary ovarian failure

 For complete information, please see full Prescribing information here.

You are leaving our website.

This link will take you to a website for which our Privacy Policy and Conditions may not apply. EMD Serono has no control over the contents and policies of third party sites or resources, and accepts no responsibility for them or for any loss or damage that may arise from your use of them. Please review the Privacy Policy and Conditions for every website you visit.